Ongoing pivotal Phase 3 study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1
FDA feedback provides direction for the comparative interim analysis
With aligned.
Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investmentsNEWARK, N.J., Dec. 14, 2023 Rafael Holdings,.
FDA launches new genetic metabolic disease advisory committee fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Get Free Report) saw a large increase in short interest in November. As of November 15th, there was short interest totalling 223,000 shares, an increase of 76.4% from the October 31st total of 126,400 shares. Currently, 2.6% of the company’s shares are sold short. Based on an average daily trading […]
APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.